Vedanta’s Phase III For Recurrent C. Diff Gets Nod To Continue

 
• By Joseph Haas
  
Vedanta's Phase III trial live biotherapeutic for recurrent C. diff infections gets DMC nod (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Trial Results

More from R&D